Pages that link to "Q58964242"
Jump to navigation
Jump to search
The following pages link to Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study (Q58964242):
Displaying 50 items.
- Adjuvant chemotherapy for advanced endometrial cancer (Q24194639) (← links)
- Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma (Q24201586) (← links)
- Adjuvant chemotherapy for endometrial cancer after hysterectomy (Q24236277) (← links)
- Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma (Q24246360) (← links)
- Chemotherapy intensity and toxicity among black and white women with advanced and recurrent endometrial cancer: a Gynecologic Oncology Group Study (Q30433480) (← links)
- A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study. (Q30442540) (← links)
- Population analysis of a 24-h paclitaxel infusion in advanced endometrial cancer: a gynaecological oncology group study (Q30443910) (← links)
- Systematic review of systemic therapy for advanced or recurrent endometrial cancer (Q33232427) (← links)
- Carboplatin and paclitaxel in advanced or metastatic endometrial cancer (Q33378748) (← links)
- A pilot study of combination chemotherapy with paclitaxel, pirarubicin, and carboplatin (TPC) for endometrial carcinoma (Q33389952) (← links)
- Endometrial cancer: what is new in adjuvant and molecularly targeted therapy? (Q33633962) (← links)
- Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer?: a Gynecologic Oncology Group ancillary data analysis (Q33671891) (← links)
- Promising novel therapies for the treatment of endometrial cancer (Q33920661) (← links)
- Artemin Reduces Sensitivity to Doxorubicin and Paclitaxel in Endometrial Carcinoma Cells through Specific Regulation of CD24. (Q34041350) (← links)
- Terpenoids from Zingiber officinale (Ginger) induce apoptosis in endometrial cancer cells through the activation of p53 (Q34541738) (← links)
- Endometrial Carcinoma: A Review of Chemotherapy, Drug Resistance, and the Search for New Agents (Q35583750) (← links)
- Effect of the molecular targeted drug, erlotinib, against endometrial cancer expressing high levels of epidermal growth factor receptor (Q35870242) (← links)
- Tetrathiomolybdate mediates cisplatin-induced p38 signaling and EGFR degradation and enhances response to cisplatin therapy in gynecologic cancers (Q36280333) (← links)
- An overview of uterine cancer and its management (Q36352068) (← links)
- Progress in gynecologic cancer research: the Gynecologic Oncology Group experience (Q36979840) (← links)
- Treatment considerations in advanced endometrial cancer (Q36996796) (← links)
- Glycogen synthase kinase 3β inhibition as a therapeutic approach in the treatment of endometrial cancer (Q37139199) (← links)
- Current treatment strategies for endometrial cancer (Q37202781) (← links)
- Surgical management and postoperative treatment of endometrial carcinoma. (Q37327982) (← links)
- Current treatment of metastatic endometrial cancer (Q37349633) (← links)
- Management of women with clear cell endometrial cancer: a Society of Gynecologic Oncology (SGO) review (Q37404153) (← links)
- Sensitivities of Uterine Adenocarcinoma, Mixed Mullerian Tumor (MMT) and Sarcoma Cell Lines to Chemotherapeutic Agents and a Flex-Het Drug (Q37409597) (← links)
- Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study (Q37429034) (← links)
- Analysis of in vitro chemoresponse assays in endometrioid endometrial adenocarcinoma: an observational ancillary analysis (Q37466261) (← links)
- Salvage intraperitoneal chemotherapy for relapsed type II endometrial cancer: A pilot case-control study (Q37489450) (← links)
- Systemic therapy for recurrent endometrial cancer: a review of North American trials (Q37546032) (← links)
- Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review (Q37547456) (← links)
- Taxanes: their impact on gynecologic malignancy (Q37692801) (← links)
- Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer (Q37699264) (← links)
- Treatment options for advanced endometrial carcinoma (Q37707615) (← links)
- Emerging drugs in endometrial cancers (Q37786618) (← links)
- Phase II study of fulvestrant in recurrent/metastatic endometrial carcinoma: a Gynecologic Oncology Group study (Q37809370) (← links)
- Medical therapy of endometrial cancer: current status and promising novel treatments. (Q37996079) (← links)
- Contemporary management of endometrial cancer (Q37996608) (← links)
- Anthracycline-based chemotherapy in metastatic endometrial carcinoma: an update (Q38061964) (← links)
- An update on the pharmacotherapy for endometrial cancer (Q38153754) (← links)
- Chemotherapy for Endometrial Cancer in Adjuvant and Advanced Disease Settings (Q38895754) (← links)
- High-Risk Endometrial Carcinoma Profiling Identifies TGF-β1 as a Key Factor in the Initiation of Tumor Invasion (Q39536386) (← links)
- Should all patients with serous and clear cell endometrial carcinoma receive adjuvant chemotherapy? (Q39811675) (← links)
- Chemosensitization of endometrial cancer cells through AKT inhibition involves FOXO1. (Q40018845) (← links)
- The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study (Q40203000) (← links)
- Racial disparity in survival of patients with uterine serous carcinoma: Changes in clinical characteristics, patterns of care and outcomes over time from 1988 to 2011. (Q40524250) (← links)
- What is an appropriate second-line regimen for recurrent endometrial cancer? Ancillary analysis of the SGSG012/GOTIC004/Intergroup study. (Q40818758) (← links)
- A phase II evaluation of flavopiridol as second-line chemotherapy of endometrial carcinoma: a Gynecologic Oncology Group study (Q46566761) (← links)
- Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma: a Gynecologic Oncology Group study (Q46754029) (← links)